Home
Learn More
Release Features
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 4, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
 
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for January 23, 2008 Subscribe to this News Feed      
 

FDA Launches Misguided Attack on Estriol, Despite Proof it is Safe and Effective for Women, says Dr. Erika

"Why would the FDA try to take estriol off the market when it is not only safe for women in menopause, it may even help women with multiple sclerosis," writes Dr Erika. Maybe it is because the agency is more concerned with protecting Wyeth than it is with protecting women, she says. Wyeth is the manufacturer of the top-selling synthetic hormone replacement therapies on the market. Earlier this month, the FDA sent warning letters to compounding pharmacies over the effectiveness of the bioidentical hormones prescribed by an increasing number of physicians. The agency also warned it is considering a ban on estriol. The FDA action was in response to a so-called "citizen's petition" sponsored by Wyeth.

New York, NY (PRWEB) January 23, 2008 - The Food and Drug Administration has launched a misguided attack on estriol despite overwhelming evidence it is safe and effective for women in menopause, according to Erika Schwartz MD at www.DrErika.com.

"Why would the FDA try to take estriol off the market when it is not only safe for women in menopause, it may even help women with multiple sclerosis," writes Dr. Erika. Maybe it is because the agency is more concerned with protecting Wyeth than it is with protecting women, she says.

Why would the FDA try to take estriol off the market when it is not only safe for women in menopause, it may even help women with multiple sclerosis
Wyeth is the manufacturer of the top-selling synthetic hormone replacement therapies on the market. Earlier this month, the FDA sent warning letters to compounding pharmacies threatening a ban on estriol. The FDA said its action was in response to a "citizen's petition" voicing concern about compounded bioidentical hormones submitted by Wyeth to the FDA October 2005.

In her blog, Dr. Erika explains what estriol is, how it works and how it has been studied in this country and overseas since the 1980s.

She notes that Jonathan Wright MD, an American leader in the field of bioidentical hormone therapies, created a combination of estriol and estradiol known as Biest to treat symptoms of menopause. The success of this combination has translated in its extensive use by compounding pharmacies around the country for the past 10 years.

Most recently estriol has been studied in the treatment of multiple sclerosis in women. It is a scientifically supported and well known fact that women who suffer with autoimmune diseases like rheumatoid arthritis, thyroiditis and MS experience significant improvement in these conditions during pregnancy. Since estriol is the dominant estrogen during pregnancy, research is presently being conducted to evaluate estriol's effect on MS.

Doses of estriol similar to those circulating in the blood stream of a pregnant woman in the middle of her pregnancy (6-8 mg/day) have shown significant remission of the disease and hold much promise. Dr. Rhonda Voskuhl at UCLA has been conducting very important estriol studies on women with MS and the results are very promising.

In an article on NeurologyReviews.com in 2002 Dr. Voskuhl was quoted as saying estriol at pregnancy doses had been given in Europe and Asia in the form of hormone replacement therapy for symptoms of menopause, "which means we didn't have to reinvent the wheel on assessing toxicity. It was very well known how this estriol preparation would be tolerated. Therefore we could go straight to a phase I clinical trials focusing on multiple sclerosis-related disease measures."

Dr. Erika says: "No adverse reactions or long term negative side-effects have been reported with the use of estriol by physicians or patients using this bioidentical hormone to the FDA to my knowledge."

Thousands of women are discovering Dr Erika at www.DrErika.com. The site helps women become strong, smart and healthy through education, empowerment and kindness.

Dr. Schwartz, its founder, is dedicated to providing an honest view on health care topics and issues from a position of devoted patient advocacy.

Dr. Schwartz is an internationally-recognized patient advocate, practicing physician, expert in conventional and integrative medicine and a frequent guest on TV and radio. She has written four books, lectures on health and wellness issues and authored a magazine column read by more than 10 million people a week.

DrErika.com delivers straight talk, smart solutions - and has no hidden agenda. It doesn't tailor its stories to suit it sponsors - it has no sponsors.

###

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/TWFnbi1QaWdnLUxvdmUtRmFsdS1Mb3ZlLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Ken Chandler
212-873-3420
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright